应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09926 康方生物
未开盘 11-18 16:08:08
63.900
-4.850
-7.05%
最高
68.050
最低
63.000
成交量
1,189万
今开
68.000
昨收
68.750
日振幅
7.35%
总市值
573.82亿
流通市值
573.82亿
总股本
8.98亿
成交额
7.65亿
换手率
1.32%
流通股本
8.98亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
康方生物(09926)下跌5.02%,报65.3元/股
金融界 · 11-18 09:40
康方生物(09926)下跌5.02%,报65.3元/股
康方生物11月15日获主力加仓1950万元 环比增加558.78%
市场透视 · 11-15
康方生物11月15日获主力加仓1950万元 环比增加558.78%
业绩向上,股价向下!生物科技股蕴藏投资机会?
财华社 · 11-13
业绩向上,股价向下!生物科技股蕴藏投资机会?
康方生物11月13日遭主力抛售2875万元 环比增加550.45%
市场透视 · 11-13
康方生物11月13日遭主力抛售2875万元 环比增加550.45%
康方生物盘中异动 早盘股价大跌5.04%报66.850港元
市场透视 · 11-13
康方生物盘中异动 早盘股价大跌5.04%报66.850港元
康方生物(09926)下跌5.04%,报66.85元/股
金融界 · 11-13
康方生物(09926)下跌5.04%,报66.85元/股
康方生物(09926)上涨3.09%,报70.05元/股
金融界 · 11-11
康方生物(09926)上涨3.09%,报70.05元/股
【券商聚焦】中泰国际:美国大选结果对医药行业多数企业影响有限
金吾财讯 · 11-08
【券商聚焦】中泰国际:美国大选结果对医药行业多数企业影响有限
浦银国际:特朗普2.0对中国医药行业的影响整体有限 CXO市场情绪或走低
智通财经 · 11-08
浦银国际:特朗普2.0对中国医药行业的影响整体有限 CXO市场情绪或走低
医药股普遍下行 金斯瑞生物科技(01548)跌超3% 第十批国采药品目录官宣 机构料续淘汰力度将加大
金吾财讯 · 11-07
医药股普遍下行 金斯瑞生物科技(01548)跌超3% 第十批国采药品目录官宣 机构料续淘汰力度将加大
交银国际:第十批国采启动报量 看好板块情绪改善+医保谈判落地后的估值修复
智通财经 · 11-07
交银国际:第十批国采启动报量 看好板块情绪改善+医保谈判落地后的估值修复
康方生物(09926)下跌3.54%,报66.8元/股
金融界 · 11-06
康方生物(09926)下跌3.54%,报66.8元/股
南向资金11月4日净卖出康方生物31.10万股 连续3日减持
市场透视 · 11-05
南向资金11月4日净卖出康方生物31.10万股 连续3日减持
异动解读 | 康方生物股价大涨5% 分析师看好旗舰新药前景
异动解读 · 11-04
异动解读 | 康方生物股价大涨5% 分析师看好旗舰新药前景
异动解读 | 小摩看好康方生物AK112 股价大涨5%
异动解读 · 11-04
异动解读 | 小摩看好康方生物AK112 股价大涨5%
康方生物(09926)上涨5.06%,报71.65元/股
金融界 · 11-04
康方生物(09926)上涨5.06%,报71.65元/股
康方生物盘中异动 股价大涨5.06%报71.650港元
市场透视 · 11-04
康方生物盘中异动 股价大涨5.06%报71.650港元
康方生物早盘涨超3% 小摩将目标价由68港元上调至74港元
新浪港股 · 11-04
康方生物早盘涨超3% 小摩将目标价由68港元上调至74港元
港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元
智通财经网 · 11-04
港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元
康方生物(09926)出现大手卖出8.5万股,成交价$70.2,涉资596.7万
阿斯达克财经 · 11-04
康方生物(09926)出现大手卖出8.5万股,成交价$70.2,涉资596.7万
暂无数据
公司概况
公司名称:
康方生物
所属市场:
SEHK
上市日期:
--
主营业务:
康方生物科技(开曼)有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":63.9,"timestamp":1731917288020,"preClose":68.75,"halted":0,"volume":11886406,"delay":0,"floatShares":898000000,"shares":898000000,"eps":2.6051574,"marketStatus":"未开盘","marketStatusCode":0,"change":-4.85,"latestTime":"11-18 16:08:08","open":68,"high":68.05,"low":63,"amount":764749451,"amplitude":0.073455,"askPrice":63.9,"askSize":99000,"bidPrice":63.8,"bidSize":15000,"shortable":3,"etf":0,"ttmEps":-0.9404132621332774,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1587657600000,"adjPreClose":68.75,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":1.951226,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926/tweets","defaultTab":"tweets","newsList":[{"id":"2484664308","title":"康方生物(09926)下跌5.02%,报65.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484664308","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484664308?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:40","pubTimestamp":1731894006,"startTime":"0","endTime":"0","summary":"11月18日,康方生物盘中下跌5.02%,截至09:40,报65.3元/股,成交8429.73万元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司,其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报,康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18094045386044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","LU0417516571.SGD","LU1794554557.SGD","LU0348783233.USD","09926","LU0348784397.USD","IE00B543WZ88.USD","LU1720050803.USD","BK1574","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2483343308","title":"康方生物11月15日获主力加仓1950万元 环比增加558.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483343308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483343308?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:16","pubTimestamp":1731658576,"startTime":"0","endTime":"0","summary":"11月15日, 康方生物股价涨1.03%,报收68.75元,成交金额3.40亿元,换手率0.55%,振幅4.92%,量比0.83。康方生物今日主力资金净流入1950万元,上一交易日主力净流入296万元,今日环比增加558.78%。该股近5个交易日上涨1.25%,主力资金累计净流入3604万元;近20日主力资金累计净流入2378万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161631a23a56cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161631a23a56cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","LU0348784397.USD","IE00B543WZ88.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","09926","LU1720050803.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"2483035330","title":"业绩向上,股价向下!生物科技股蕴藏投资机会?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483035330","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483035330?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:28","pubTimestamp":1731497301,"startTime":"0","endTime":"0","summary":"美东时间11月12日,再鼎医药(ZLAB.US)大跌6.85%,百济神州(BGNE.US)则下跌5.56%。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202411_1/91399957-d986-4ce3-a87a-53e008f85886.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202411_1/91399957-d986-4ce3-a87a-53e008f85886.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67348d5553243c06d087f4a7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK4139","LU0417516571.SGD","LU1794554557.SGD","LU1969619763.USD","LU2328871848.SGD","BK1588","BK4504","LU0307460666.USD","IE00B543WZ88.USD","BK1574","BK1161","BK1583","BK4585","LU0348783233.USD","09926","LU0348784397.USD","LU1720050803.USD","BK4548","09969","LU0588546209.SGD","09688","BK1500","06160","BK4535","BK4588","BK4505","BGNE","BK4526","LU2488822045.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2483002496","title":"康方生物11月13日遭主力抛售2875万元 环比增加550.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483002496","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483002496?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:16","pubTimestamp":1731485796,"startTime":"0","endTime":"0","summary":"11月13日, 康方生物股价跌4.05%,报收67.55元,成交金额4.60亿元,换手率0.76%,振幅5.89%,量比1.29。康方生物今日主力资金净流出2875万元,上一交易日主力净流出442万元,今日环比增加550.45%。该股近5个交易日上涨1.19%,主力资金累计净流入2201万元;近20日主力资金累计净流入3030万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161702a23324af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161702a23324af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","IE00B543WZ88.USD","LU0348783233.USD","IE00B5MMRT66.SGD","BK1574","09926","LU0348784397.USD","LU0417516571.SGD","LU1794554557.SGD","BK1161","LU2488822045.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2483015112","title":"康方生物盘中异动 早盘股价大跌5.04%报66.850港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483015112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483015112?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:25","pubTimestamp":1731464728,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时25分,康方生物股票出现异动,股价急速下跌5.04%。截至发稿,该股报66.850港元/股,成交量251.4万股,换手率0.28%,振幅4.47%。资金方面,该股资金流入4304万港元,流出9876.82万港元。康方生物股票所在的生物技术行业中,整体跌幅为2.09%。其相关个股中,腾盛博药-B、贝康医疗-B、华康生物医学涨幅较大,振幅较大的相关个股有宜明昂科-B、腾盛博药-B、乐普生物-B,振幅分别为19.44%、12.96%、11.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310252898e423fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310252898e423fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348784397.USD","IE00BPRC5H50.USD","BK1161","BK1574","LU0417516571.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348783233.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU2488822045.USD","09926"],"gpt_icon":0},{"id":"2483024013","title":"康方生物(09926)下跌5.04%,报66.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483024013","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483024013?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:25","pubTimestamp":1731464727,"startTime":"0","endTime":"0","summary":"11月13日,康方生物盘中下跌5.04%,截至10:25,报66.85元/股,成交1.7亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司,其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报,康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13102545231716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B5MMRT66.SGD","LU0348784397.USD","LU0417516571.SGD","LU0348783233.USD","LU1720050803.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD","09926","IE00BPRC5H50.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"2482230392","title":"康方生物(09926)上涨3.09%,报70.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482230392","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482230392?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:06","pubTimestamp":1731301566,"startTime":"0","endTime":"0","summary":"11月11日,康方生物盘中上涨3.09%,截至13:06,报70.05元/股,成交3.01亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司,其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报,康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/11130645138221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926","LU1720050803.USD","IE00B543WZ88.USD","LU1794554557.SGD","IE00BPRC5H50.USD","BK1161","LU0348783233.USD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348784397.USD"],"gpt_icon":0},{"id":"2481314153","title":"【券商聚焦】中泰国际:美国大选结果对医药行业多数企业影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2481314153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481314153?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:06","pubTimestamp":1731053203,"startTime":"0","endTime":"0","summary":"目前医药行业中除医药研发外包服务板块可能受美国生物法案的影响外,其他板块由于多数企业主要收入源在中国,受地缘政治影响不大。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0348784397.USD","BK1161","CXO","BK1191","LU0348783233.USD","LU1794554557.SGD","BK1521","IE00BPRC5H50.USD","BK1574","IE00B5MMRT66.SGD","BK1515","LU2488822045.USD","LU0417516571.SGD","01177","IE00B543WZ88.USD","09926","LU1720050803.USD","BK1589","03692"],"gpt_icon":0},{"id":"2481146828","title":"浦银国际:特朗普2.0对中国医药行业的影响整体有限 CXO市场情绪或走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2481146828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481146828?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:36","pubTimestamp":1731051361,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,浦银国际发布研报称,美国大选结果已于北京时间11月6日揭晓,特朗普当选新一届美国总统。特朗普当选后,该行认为《生物安全法案》单独立法概率较此前有所提升,草案或更快完成立法程序,在大选后交接期间通过的概率有所上升,因此,药明系股票及CXO行业市场情绪或将短期内走低。若美国后续加征关税,该行认为对企业业绩的实质影响相对有限。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK1574","BK0028","LU1720050803.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK0250","BK1585","600056","BK0010","01858","BK1161","BK0185","LU0348783233.USD","LU1794554557.SGD","BK1587","BK1588","BK1100","BK1191","BK0188","02190","09926","LU0348784397.USD","IE00BPRC5H50.USD","LU0417516571.SGD","BK1583","00013","LU2488822045.USD","BK0175","CXO"],"gpt_icon":0},{"id":"2481994090","title":"医药股普遍下行 金斯瑞生物科技(01548)跌超3% 第十批国采药品目录官宣 机构料续淘汰力度将加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2481994090","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481994090?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:54","pubTimestamp":1730944476,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍下行,荣昌生物 跌4.09%,药明巨诺、金斯瑞生物科技跌超3%,基石药业、百济神州跌逾2%,和黄医药跌1.55%,先声药业跌1.47%,康方生物跌1.19%,云顶新耀跌1.08%。2024年国家医保药品目录调整现场谈判已结束,新目录预计11月底公布,明年1月1日正式实施,涉及127家企业162种药品。此次国采品种数量和入围门槛均为历史之最,预计后续淘汰力度将加大,注射剂比例创新高,将改变相关药企的竞争格局。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947254","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","IE00B5MMRT66.SGD","BK1515","LU0348783233.USD","BK1574","LU1794554557.SGD","BK1588","00013","IE00BPRC5H50.USD","HK0000306685.HKD","02096","HK0000320223.HKD","HK0000306701.USD","HK0000320264.USD","LU0417516571.SGD","06160","BK1161","09926","02616","BK1583","01952","BK1576","09939","BK1500","BK1587","IE00B543WZ88.USD","BK1191","159938","LU0348784397.USD","BK1141","LU1969619763.USD","09995","LU0307460666.USD","LU2328871848.SGD","LU0588546209.SGD","02126","LU2488822045.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2481940999","title":"交银国际:第十批国采启动报量 看好板块情绪改善+医保谈判落地后的估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2481940999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481940999?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:19","pubTimestamp":1730942392,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,交银国际发布研究报告称,11月1日,药品联合采购办公室发布《关于开展第十批国家组织药品集中采购相关药品信息填报工作的通知》,宣布第十批国采正式启动。报告中称,2024年国家医保药品目录调整现场谈判结束。新版医保药品目录预计于11月底对外发布,明年1月1日起正式实施。此次谈判时间为10月27日到30日中午,共涉及127家企业、162种药品,其中医保目录外药品117种,医保目录内谈判续约药品45种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","BK1147","LU1794554557.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","LU0417516571.SGD","LU0348783233.USD","00013","03329","01952","BK1574","02096","BK1588","IE00BPRC5H50.USD","LU0348784397.USD","BK1583","IE00B543WZ88.USD","LU2488822045.USD","BK1587","BK1161","BK1191"],"gpt_icon":0},{"id":"2481472628","title":"康方生物(09926)下跌3.54%,报66.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481472628","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481472628?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:52","pubTimestamp":1730879571,"startTime":"0","endTime":"0","summary":"11月6日,康方生物盘中下跌3.54%,截至15:52,报66.8元/股,成交3.0亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司,其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报,康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/06155244989121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0348784397.USD","IE00BPRC5H50.USD","BK1161","BK1574","LU0417516571.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348783233.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU2488822045.USD","09926"],"gpt_icon":0},{"id":"2481447591","title":"南向资金11月4日净卖出康方生物31.10万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481447591","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481447591?lang=zh_cn&edition=full","pubTime":"2024-11-05 09:30","pubTimestamp":1730770221,"startTime":"0","endTime":"0","summary":"11月4日,南向资金减持康方生物31.10万股连续3日减持。截止当日收盘,港股通共持有康方生物31332.05万股,占流通股34.90%。康方生物近5个交易日上涨1.02%,港股通累计增持112.23万股;近20个交易日下跌6.38%,港股通累计增持859.42万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105093323a2165f00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105093323a2165f00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348783233.USD","IE00B5MMRT66.SGD","BK1161","BK1574","LU1720050803.USD","09926","LU1794554557.SGD","LU0348784397.USD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"1150738228","title":"异动解读 | 康方生物股价大涨5% 分析师看好旗舰新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1150738228","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150738228?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:16","pubTimestamp":1730711794,"startTime":"0","endTime":"0","summary":"康方生物今日股价盘中大涨5.28%,一度升至71.65港元。分析师表示,这一涨势主要源于市场对康方生物旗舰在研新药AK112的乐观期待。摩根大通等多家分析机构发布研究报告,看好AK112扩大适应症范围后的发展前景。基于上述预期,这些机构上调了AK112未来销售预测,同时将康方生物目标股价上调至74港元左右,给予\"增持\"评级。投资者对AK112适应症和市场空间的扩大表现出积极反应,这成为推动公司股价大涨的主因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"gpt_icon":0},{"id":"1143049433","title":"异动解读 | 小摩看好康方生物AK112 股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143049433","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143049433?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:46","pubTimestamp":1730684788,"startTime":"0","endTime":"0","summary":"康方生物今日股价盘中大涨5.06%,截至发稿时,股价报70.2港元。引发康方生物大涨的主因是,摩根大通发布研究报告看好该公司旗下在研新药AK112的发展前景。基于此,摩根大通上调AK112于2028至2033年的销售预测,并将康方生物的目标价从68港元上调至74港元,维持\"增持\"评级。市场对于AK112拥有更广阔的适应症和市场空间表现出积极反应,促使康方生物股价今日大涨。投资者认为,一旦AK112成功上市,其在肺癌治疗领域的市场前景可期,从而推动该股价格向上。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"gpt_icon":0},{"id":"2480310057","title":"康方生物(09926)上涨5.06%,报71.65元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480310057","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480310057?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:44","pubTimestamp":1730684643,"startTime":"0","endTime":"0","summary":"11月4日,康方生物盘中上涨5.06%,截至09:44,报71.65元/股,成交1.46亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司,其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报,康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/04094444885745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926","IE00BPRC5H50.USD","LU1720050803.USD","LU0348784397.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348783233.USD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2480931028","title":"康方生物盘中异动 股价大涨5.06%报71.650港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480931028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480931028?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:44","pubTimestamp":1730684642,"startTime":"0","endTime":"0","summary":"2024年11月04日早盘09时44分,康方生物股票出现异动,股价急速上涨5.06%。截至发稿,该股报71.650港元/股,成交量205.781万股,换手率0.23%,振幅3.08%。资金方面,该股资金流入8123.24万港元,流出3833.24万港元。康方生物股票所在的生物技术行业中,整体涨幅为0.15%。其相关个股中,昭衍新药、华领医药-B、云顶新耀-B涨幅较大,振幅较大的相关个股有昭衍新药、方达控股、科济药业-B,振幅分别为20.62%、13.48%、8.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110409440298e40286&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d687eec3b8c9c2cb79b216c38e84ebbe","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110409440298e40286&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU2488822045.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","BK1574","BK1161","09926","LU1720050803.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2480231026","title":"康方生物早盘涨超3% 小摩将目标价由68港元上调至74港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480231026","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480231026?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:41","pubTimestamp":1730684460,"startTime":"0","endTime":"0","summary":" 康方生物早盘高开近3%,截至发稿,股价上涨3.45%,现报70.55港元,成成交额1.03亿港元。 该行认为,新进展是对AK112发展潜力的又一次信心证明,考虑到约70%的NSCLC患者属于非鳞状类别,将该因素纳入AK112的海外市场预测模型后,目前预测AK112在美国市场销售潜力最多增加9亿美元,2028至2033年销售额预测亦上调3%至6%,目标价相应由68港元上调至74港元,评级“增持”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-04/doc-incuwfya3314460.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":"d687eec3b8c9c2cb79b216c38e84ebbe","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-04/doc-incuwfya3314460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09926"],"gpt_icon":0},{"id":"2480317433","title":"港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480317433","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480317433?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:26","pubTimestamp":1730683608,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康方生物高开近3%,截至发稿,涨2.93%,报70.2港元,成交额596.7万港元。该行认为,新进展是对AK112发展潜力的又一次信心证明,考虑到约70%的NSCLC患者属于非鳞状类别,将该因素纳入AK112的海外市场预测模型后,目前预测AK112在美国市场销售潜力最多增加9亿美元,2028至2033年销售额预测亦上调3%至6%,目标价相应由68港元上调至74港元,评级“增持”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0882574139.USD","LU","IE00BWXC8680.SGD","IE000M9KFDE8.USD","LU0106831901.USD","LU0971096721.USD","IE00BJTD4N35.SGD","LU0170899867.USD","BK4207","IE0034235188.USD","LU2488822045.USD","BK1161","LU1119994496.HKD","LU0348783233.USD","LU0348784397.USD","LU0211326755.USD","LU0215105999.USD","LU0417517546.SGD","BK4581","IE00B3S45H60.SGD","IE00B5MMRT66.SGD","LU0238689110.USD","LU0976567544.SGD","LU1794554557.SGD","IE00BKVL7J92.USD","09926","LU0149725797.USD","BK4566","IE00BYXW3230.USD","LU0208291251.USD","LU0234572021.USD","LU0417516571.SGD","LU0070302665.USD","BK4588","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU1084165304.USD","IE00B543WZ88.USD","IE00BFXG1179.USD","IE00BLSP4239.USD","BK4550","BK4534","IE00BPRC5H50.USD","LU1064131342.USD","LU0320765489.SGD","LU0211331839.USD","IE0034235295.USD","LU0496365809.HKD","IE0034235303.USD","IE00BDCRKT87.USD"],"gpt_icon":0},{"id":"2480531777","title":"康方生物(09926)出现大手卖出8.5万股,成交价$70.2,涉资596.7万","url":"https://stock-news.laohu8.com/highlight/detail?id=2480531777","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480531777?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:20","pubTimestamp":1730683200,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午09:20出现大手卖出,成交量为8.5万,成交价为港币$70.2,涉资596.7万。至目前为止,股价升2.933%,今日最高价为$70.2,而最低价为$70.2,总成交量为8.5万股,总成交金额港币$596.7万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT24110419/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09926","LU1720050803.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","LU0417516571.SGD","BK1161","IE00BPRC5H50.USD","LU0348783233.USD","LU0348784397.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0949},{"period":"1month","weight":-0.0766},{"period":"3month","weight":0.4153},{"period":"6month","weight":0.351},{"period":"1year","weight":0.3654},{"period":"ytd","weight":0.3772}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技(开曼)有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000127},{"month":2,"riseRate":0.25,"avgChangeRate":-0.01324},{"month":3,"riseRate":0.25,"avgChangeRate":-0.055315},{"month":4,"riseRate":0.75,"avgChangeRate":0.01855},{"month":5,"riseRate":0.4,"avgChangeRate":0.001922},{"month":6,"riseRate":0.6,"avgChangeRate":0.140431},{"month":7,"riseRate":0.4,"avgChangeRate":-0.03083},{"month":8,"riseRate":0.4,"avgChangeRate":-0.010728},{"month":9,"riseRate":0.6,"avgChangeRate":0.062076},{"month":10,"riseRate":0.6,"avgChangeRate":0.094612},{"month":11,"riseRate":1,"avgChangeRate":0.076593},{"month":12,"riseRate":0.5,"avgChangeRate":0.104965}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}